Renaud Burrer

Renaud Burrer has a diverse work experience that spans over several companies and roles. In 1997, they started as a PHD student at the Inserm U74 laboratory, where they focused on neutralizing antibodies until 2003. From 2002 to 2007, Renaud worked as a Postdoctoral Researcher at The Scripps Research Institute, conducting further independent research. In 2007, they moved to CIML as a Postdoctoral Researcher. Renaud then joined INSERM in 2008, where they led startup creation projects as a Project Leader until 2009. From 2010 to 2011, they worked as a Valorization Engineer at the Centre national de la recherche scientifique. Renaud then joined Ciloa SAS as a Project Manager, focusing on exosome production, monoclonal antibody/vaccine development, from 2011 to 2016. In 2017, they became the Head of R&D at Histalim, a histology services company, a role they held until 2020. Renaud Burrer's most recent work experience includes being the Chief Scientific Officer at Cerba Research from 2019 to 2020, and currently serving as the Global Head of Histopathology and the General Manager of the Montpellier Laboratory at Cerba Research since 2020.

Renaud Burrer's education history includes the following chronological information:

- From 2021 to 2022, Renaud Burrer attended emlyon business school, where they pursued a degree in Business Administration and Management, specifically in the field of Biomanager School.

- From 1998 to 2002, Renaud Burrer studied at Université Louis Pasteur, Strasbourg, where they earned a PhD in Virology - Immunology.

- In 1997-1998, Renaud Burrer also attended Université Louis Pasteur, Strasbourg, and obtained a Master 2 (DEA) in Molecular Biology.

- Additionally, in 1996-1997, Renaud Burrer pursued a Master 1 degree in Applied Microbiology at Université Louis Pasteur, Strasbourg.